FDA Announces Key Actions to Advance Development of Novel Co
SILVER SPRING, Md., Jan. 27, 2020 /PRNewswire/ -- Today, the U.S. Food and Drug Administration (FDA) announced critical actions to advance development of novel coronavirus medical countermeasures.
As with any emerging public health threat, the FDA will collaborate with interagency partners, product developers, international partners and global regulators to expedite the development and availability of medical products needed to diagnose, treat, mitigate and prevent such outbreaks.
"We have a vital mission to protect and promote public health and the FDA is closely collaborating with our domestic and international public health partners to mitigate the impact of the novel coronavirus that emerged in Wuhan, China," said FDA Commissioner Stephen M. Hahn, M.D. "We are actively leveraging the vast breadth of the FDA's expertise and have begun employing the full range of our public health authorities to facilitate the development and availability of investigational medical products to help address this urgent public health situation."
As part of FDA's ongoing commitment to prepare and respond to infectious disease outbreaks, the agency is sharing updates on processes in place to help developers understand the pathways, including Emergency Use Authorization (EUA), that may be available to more rapidly advance and make medical countermeasures available for this virus, including diagnostic tests.
The FDA is also issuing key information for the public to help support the timely development of medical products to respond to the current outbreak. In order to support efficient medical product development for novel coronavirus medical countermeasures, today the FDA is launching a landing page that provides key information for the public, including product developers, on the FDA's efforts in response to this outbreak.
"We are committed to keeping the American people informed as we prepare and respond to emerging public health threats, including the novel coronavirus," said FDA Deputy Commissioner of Policy, Legislation and International Affairs Anna Abram. "The agency is committed to ensuring safe and effective medical countermeasures are available as quickly as possible to protect public health."
Being able to quickly and accurately diagnose patients infected with the novel coronavirus is an essential step in helping patients identify the need for care and mitigate the spread of the virus to additional individuals. Currently, there are no commercially available products that are authorized to detect novel coronavirus; however, the FDA is actively working to facilitate the development and availability of diagnostics that can detect this virus. The agency is working with public health partners to advance and share the reference materials necessary to facilitate diagnostic development.
The FDA is also requesting that diagnostic test sponsors interested in potential EUA for tests to detect 2019-nCoV contact [email protected] for further information and templates.
Sponsors wishing to develop therapeutics for 2019-nCoV are encouraged to submit information and questions via the FDA's Pre-IND Consultation program.
- 2019 Novel Coronavirus (2019-nCoV)
- How to Submit a Pre-EUA for In vitro Diagnostics to FDA
- Emergency Use Authorization
- 2019 Novel Coronavirus, Wuhan, China (CDC)
Contact: Megan McSeveney, 240-402-4514, [email protected]
The FDA is an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.
View original content to download multimedia:http://www.prnewswire.com/news-releases/fda-announces-key-actions-to-advance-development-of-novel-coronavirus-medical-countermeasures-300993926.html
SOURCE U.S. Food and Drug Administration